全文获取类型
收费全文 | 268059篇 |
免费 | 21367篇 |
国内免费 | 8710篇 |
专业分类
耳鼻咽喉 | 2050篇 |
儿科学 | 8935篇 |
妇产科学 | 1860篇 |
基础医学 | 23022篇 |
口腔科学 | 4045篇 |
临床医学 | 28610篇 |
内科学 | 62214篇 |
皮肤病学 | 3180篇 |
神经病学 | 27813篇 |
特种医学 | 7349篇 |
外国民族医学 | 5篇 |
外科学 | 27684篇 |
综合类 | 38947篇 |
现状与发展 | 31篇 |
一般理论 | 11篇 |
预防医学 | 19648篇 |
眼科学 | 2503篇 |
药学 | 20106篇 |
213篇 | |
中国医学 | 14955篇 |
肿瘤学 | 4955篇 |
出版年
2024年 | 491篇 |
2023年 | 5138篇 |
2022年 | 7144篇 |
2021年 | 13929篇 |
2020年 | 12865篇 |
2019年 | 10187篇 |
2018年 | 9947篇 |
2017年 | 10037篇 |
2016年 | 10574篇 |
2015年 | 10254篇 |
2014年 | 19625篇 |
2013年 | 20891篇 |
2012年 | 16034篇 |
2011年 | 17489篇 |
2010年 | 13843篇 |
2009年 | 13019篇 |
2008年 | 12865篇 |
2007年 | 12498篇 |
2006年 | 11187篇 |
2005年 | 9287篇 |
2004年 | 7830篇 |
2003年 | 6730篇 |
2002年 | 5637篇 |
2001年 | 4946篇 |
2000年 | 4028篇 |
1999年 | 3500篇 |
1998年 | 3218篇 |
1997年 | 2812篇 |
1996年 | 2585篇 |
1995年 | 2319篇 |
1994年 | 2157篇 |
1993年 | 1817篇 |
1992年 | 1733篇 |
1991年 | 1547篇 |
1990年 | 1253篇 |
1989年 | 1095篇 |
1988年 | 988篇 |
1987年 | 901篇 |
1986年 | 770篇 |
1985年 | 889篇 |
1984年 | 777篇 |
1983年 | 476篇 |
1982年 | 570篇 |
1981年 | 469篇 |
1980年 | 393篇 |
1979年 | 345篇 |
1978年 | 254篇 |
1977年 | 236篇 |
1976年 | 193篇 |
1975年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
Michael Staehler Peter J. Goebell Lothar Müller Till-Oliver Emde Natalie Wetzel Lisa Kruggel Martina Jänicke Norbert Marschner the RCC-Registry Group 《International journal of cancer. Journal international du cancer》2020,146(5):1307-1315
Non-clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non-clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first- and second-line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC-Registry), 99 patients with papillary mRCC treated with systemic first-line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first-line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression-free survival from start of first-line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow-up, and 9% were alive at the end of the individual 3-year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real-world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC. 相似文献
62.
63.
Martin R. Späth Malte P. Bartram Nicolàs Palacio-Escat K. Johanna R. Hoyer Cedric Debes Fatih Demir Christina B. Schroeter Amrei M. Mandel Franziska Grundmann Giuliano Ciarimboli Andreas Beyer Jayachandran N. Kizhakkedathu Susanne Brodesser Heike Göbel Jan U. Becker Thomas Benzing Bernhard Schermer Martin Höhne Markus M. Rinschen 《Kidney international》2019,95(2):333-349
64.
《The Journal for Nurse Practitioners》2019,15(1):65-72
Valvular heart disease affects patients of all ages, with the highest incidence in patients older than 75 years. The nurse practitioner, whether in the primary or acute care setting, plays a vital role in the detection, monitoring, and shared decisions in treatment options. Assessment skills in conjunction with appropriate testing can identify patients early in the trajectory of the disease. The purpose of this article is to provide tips for history-taking and physical exam techniques, identify appropriate diagnostic testing, and review treatment options for adults with valvular heart disease. 相似文献
65.
66.
Alzheimer’s disease is characterized by the extracellular accumulation of the amyloidβin the form of amyloid plaques and the intracellular deposition of the microtubule-associated protein tau in the form of neurofibrillary tangles.Most of the Alzheimer’s drugs targeting amyloidβhave been failed in clinical trials.Particularly,tau pathology connects greatly in the pathogenesis of Alzheimer’s disease.Tau protein enhances the stabilization of microtubules that leads to the appropriate function of the neuron.Changes in the quantity or the conformation of tau protein could affect its function as a microtubules stabilizer and some of the processes wherein it is involved.The molecular mechanisms leading to the accumulation of tau are principally signified by numerous posttranslational modifications that change its conformation and structural state.Therefore,aberrant phosphorylation,as well as truncation of tau protein,has come into focus as significant mechanisms that make tau protein in a pathological entity.Furthermore,the shape-shifting nature of tau advocates to comprehend the progression of Alzheimer’s disease precisely.In this review,we emphasize the recent studies about the toxic and shape-shifting nature of tau in the pathogenesis of Alzheimer’s disease. 相似文献
67.
68.
目的:观察清肝解郁和健脾补肾法治疗肝火上亢型慢性肾衰(CRF)合并高血压患者的临床效果。方法:选取2016年6月至2018年6月京东誉美医院收治的肝火上亢型CRF合并高血压患者90例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组45例。对照组给予口服硝苯地平控释片治疗,观察组在对照组治疗基础上给予清肝解郁、健脾补肾汤治疗,每4周为1个疗程,均治疗3个疗程。比较治疗前后中医症状评分、收缩压(SBP)、舒张压(DBP)变化;比较2组临床疗效;比较治疗前后肾功能指标:尿素氮(BUN)、血肌酐(Scr)、24 h尿蛋白定量(24 hPRO);统计治疗期间2组不良反应发生情况。结果:治疗前观察组与对照组中医症状评分、SBP、DBP、BUN、Scr、24 hPRO比较,差异均无统计学意义(P>0.05),治疗后2组患者中医症状评分、SBP、DBP、BUN、Scr、24 hPRO均显著降低(P<0.05),观察组均低于对照组,差异有统计学意义(P<0.05);2组临床疗效比较,差异有统计学意义(P<0.05),且观察组总有效率显著高于对照组,差异有统计学意义(P<0.05);观察组和对照组不良反应发生率分别为2.22%和6.67%,2组比较差异无统计学意义(P>0.05)。结论:清肝解郁、健脾补肾法辅助治疗肝火上亢型CRF合并高血压疗效确切,可较好控制血压,并且可显著改善肾功能,减少不良反应发生情况。 相似文献
69.
目的:探究复方丹参滴丸对老年冠心病患者血流变学、血脂及炎性反应递质的影响。方法:选取2015年1月至2017年12月海南省人民医院收治的老年冠心病患者154例作为研究对象,按照随机数字表法随机分为对照组和观察组,每组77例。对照组采用常规西药治疗,观察组在此基础上加服复方丹参滴丸。比较治疗前后2组患者的血流变学、血脂、炎性反应递质和疗效。结果:观察组治疗有效率为92.21%,明显高于对照组治疗有效率79.22%,差异有统计学意义(P<0.05)。治疗后,2组总胆固醇(TC)、三酰甘油(TG)和低密度脂蛋白(LDL)水平均升高,差异有统计学意义(P<0.05),且观察组高于对照组,2组差异有统计学意义(P<0.05)。2组血流变学指标、高密度脂蛋白(HDL)、IL-6和TNF-α水平治疗后均降低(P<0.05),且观察组降低更明显,差异有统计学意义(P<0.05)。结论:复方丹参滴丸联合常规西药治疗冠心病患者,能够调节脂代谢,降低炎性反应,改善血流变学。 相似文献
70.